Evidence map›Paper›PMID 39721034›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Concurrent Amplification of Ferroptosis and Immune System Activation Via Nanomedicine-Mediated Radiosensitization for Triple-Negative Breast Cancer Therapy.

Reyida Aishajiang, Zhongshan Liu, Yuan Liang, Pengye Du, Yi Wei, Xiqian Zhuo, Shuyu Liu, Pengpeng Lei, Tiejun Wang, Duo Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Reyida AishajiangDepartment of Radiotherapy, The Second Hospital of Jilin University, Changchun, 130022, China.ORCID https://orcid.org/0000-0001-9496-3905
Zhongshan LiuDepartment of Radiotherapy, The Second Hospital of Jilin University, Changchun, 130022, China.
Yuan LiangState Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China.
Pengye DuState Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China.
Yi WeiState Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China.
Xiqian ZhuoDepartment of Radiotherapy, The Second Hospital of Jilin University, Changchun, 130022, China.
Shuyu LiuState Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China.
Pengpeng LeiState Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China.ORCID https://orcid.org/0000-0002-7091-5199
Tiejun WangDepartment of Radiotherapy, The Second Hospital of Jilin University, Changchun, 130022, China.ORCID https://orcid.org/0009-0003-4995-5684
Duo YuDepartment of Radiotherapy, The Second Hospital of Jilin University, Changchun, 130022, China.ORCID https://orcid.org/0009-0000-0869-1940

Funding

Jilin Province Development and Reform Commission YDZJ202402068CXJDJilin Province Youth Science and Technology Talent support project QT202229Jilin Provincial Health and Family Planning Commission 2022LC115Jilin Provincial Scientific and Technological Development Program 419161923009National Natural Science Foundation of China 52371254
6 · The paper itself

Abstract

Radiation therapy (RT) is one of the core therapies for current cancer management. However, the emergence of radioresistance has become a major cause of radiotherapy failure and disease progression. Therefore, overcoming radioresistance to achieve highly effective treatment for refractory tumors is significant yet challenging. Here, pH-responsive DSPE-PEoz modified hollow Bi

Indexed as

FerroptosisNanomedicineRadiation-Sensitizing AgentsTriple Negative Breast NeoplasmsAnimalsCell Line, TumorFemaleHumansMiceReactive Oxygen SpeciesTumor MicroenvironmentRadiation-Sensitizing AgentsReactive Oxygen SpeciescGAS‐STING pathwayferroptosisnanomedicineradiation therapyROS

Identifiers

PMID39721034
PMCPMC11831504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.